Current evidence suggests a potential shift in the therapeutic landscape of CRC, and immunotherapy benefits may extend beyond MSI-H tumors, offering new possibilities for the broader population of patients with MSS CRC.
Thaís Sampaio Corrêa de Almeida, Maria Ignez de Melro Freitas Braghiroli, J. Sabbaga et al.· American Journal of Clinical...· 0 citations
Current FDA-approved treatments for CCA include therapies targeting HER2, IDH1, FGFR2, and other key biomarkers, including therapies targeting HER2, IDH1, FGFR2, and other key biomarkers.
Augusto Almeida, Joao Manzi, Camila Hoff et al.· Translational Oncology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.